Leibovitch SA - Search Results

1

Identification of essential sequences for cellular localization in the muscle-specific ubiquitin E3 ligase MAFbx/Atrogin 1.

Julie LC, Sabrina BP, Marie-Pierre L, Leibovitch SA. Julie LC, et al. Among authors: leibovitch sa. FEBS Lett. 2012 Feb 17;586(4):362-7. doi: 10.1016/j.febslet.2011.12.031. Epub 2012 Jan 11. FEBS Lett. 2012. PMID: 22249105 Free article.

2

Inhibition of atrogin-1/MAFbx mediated MyoD proteolysis prevents skeletal muscle atrophy in vivo.

Lagirand-Cantaloube J, Cornille K, Csibi A, Batonnet-Pichon S, Leibovitch MP, Leibovitch SA. Lagirand-Cantaloube J, et al. Among authors: leibovitch sa. PLoS One. 2009;4(3):e4973. doi: 10.1371/journal.pone.0004973. Epub 2009 Mar 25. PLoS One. 2009. PMID: 19319192 Free PMC article.

3

Degradation of MyoD mediated by the SCF (MAFbx) ubiquitin ligase.

Tintignac LA, Lagirand J, Batonnet S, Sirri V, Leibovitch MP, Leibovitch SA. Tintignac LA, et al. Among authors: leibovitch sa, leibovitch mp. J Biol Chem. 2005 Jan 28;280(4):2847-56. doi: 10.1074/jbc.M411346200. Epub 2004 Nov 5. J Biol Chem. 2005. PMID: 15531760 Free article.

4

MAFbx/Atrogin-1 controls the activity of the initiation factor eIF3-f in skeletal muscle atrophy by targeting multiple C-terminal lysines.

Csibi A, Leibovitch MP, Cornille K, Tintignac LA, Leibovitch SA. Csibi A, et al. Among authors: leibovitch sa. J Biol Chem. 2009 Feb 13;284(7):4413-21. doi: 10.1074/jbc.M807641200. Epub 2008 Dec 10. J Biol Chem. 2009. PMID: 19073596 Free article.

5

The initiation factor eIF3-f is a major target for atrogin1/MAFbx function in skeletal muscle atrophy.

Lagirand-Cantaloube J, Offner N, Csibi A, Leibovitch MP, Batonnet-Pichon S, Tintignac LA, Segura CT, Leibovitch SA. Lagirand-Cantaloube J, et al. Among authors: leibovitch sa. EMBO J. 2008 Apr 23;27(8):1266-76. doi: 10.1038/emboj.2008.52. Epub 2008 Mar 20. EMBO J. 2008. PMID: 18354498 Free PMC article.

6

Signal-induced ubiquitination of p57(Kip2) is independent of the C-terminal consensus Cdk phosphorylation site.

Leibovitch MP, Kannengiesser C, Leibovitch SA. Leibovitch MP, et al. Among authors: leibovitch sa. FEBS Lett. 2003 May 22;543(1-3):125-8. doi: 10.1016/s0014-5793(03)00425-3. FEBS Lett. 2003. PMID: 12753918 Free article.

7

eIF3-f function in skeletal muscles: to stand at the crossroads of atrophy and hypertrophy.

Csibi A, Tintignac LA, Leibovitch MP, Leibovitch SA. Csibi A, et al. Among authors: leibovitch sa. Cell Cycle. 2008 Jun 15;7(12):1698-701. doi: 10.4161/cc.7.12.6090. Epub 2008 Jun 11. Cell Cycle. 2008. PMID: 18583931

8

eIF3f: a central regulator of the antagonism atrophy/hypertrophy in skeletal muscle.

Sanchez AM, Csibi A, Raibon A, Docquier A, Lagirand-Cantaloube J, Leibovitch MP, Leibovitch SA, Bernardi H. Sanchez AM, et al. Among authors: leibovitch sa. Int J Biochem Cell Biol. 2013 Oct;45(10):2158-62. doi: 10.1016/j.biocel.2013.06.001. Epub 2013 Jun 13. Int J Biochem Cell Biol. 2013. PMID: 23769948 Free PMC article. Review.

9

The translation regulatory subunit eIF3f controls the kinase-dependent mTOR signaling required for muscle differentiation and hypertrophy in mouse.

Csibi A, Cornille K, Leibovitch MP, Poupon A, Tintignac LA, Sanchez AM, Leibovitch SA. Csibi A, et al. Among authors: leibovitch sa. PLoS One. 2010 Feb 1;5(2):e8994. doi: 10.1371/journal.pone.0008994. PLoS One. 2010. PMID: 20126553 Free PMC article.

10

Overexpression of Mos(rat) proto-oncogene product enhances the positive autoregulatory loop of MyoD.

Benayoun B, Pelpel K, Solhonne B, Guillier M, Leibovitch SA. Benayoun B, et al. Among authors: leibovitch sa. FEBS Lett. 1998 Oct 16;437(1-2):39-43. doi: 10.1016/s0014-5793(98)01192-2. FEBS Lett. 1998. PMID: 9804168 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

70 results

Search Page